Beyond Borders, Beyond Bias: Why Indian Clinical Data Holds Up in Global Filings

For decades, global clinical development has carried an unspoken assumption that evidence generated closer to the target market is inherently more reliable than evidence generated farther away. Proximity has often been treated as a proxy for relevance. Indian clinical data, despite meeting international standards, have therefore been viewed through a lens of distance rather than design.

This proximity lens is now increasingly outdated.

In modern regulatory practice, the central question is no longer how close a study is conducted to a target market, but how well its data can be interpreted, justified, and extrapolated. The persistence of proximity bias says less about regulatory science and more about inherited perceptions that do not align with how evidence is actually evaluated today.

From Proximity to Interpretability

Contemporary regulatory frameworks do not privilege geography; they privilege interpretability. This shift is explicitly articulated in the ICH E5 guideline, which reframes ethnic and regional factors as variables to be evaluated for clinical relevance, rather than barriers to acceptance. The guidance does not ask whether data originates nearby, but whether population differences meaningfully affect pharmacology, biological response, or endpoint interpretation.¹

In practice, this means that Indian clinical data are assessed on the same scientific criteria as data generated anywhere in Western countries: study design, endpoint relevance, biological plausibility, and control of variability. When these elements are robust, distance becomes largely irrelevant.

How Indian Clinical Studies Support Global Filings

Indian clinical studies increasingly support global regulatory filings because they are designed around objective, mechanism-driven endpoints rather than culturally sensitive or perception-dependent outcomes. This alignment mirrors how regulators evaluate evidence in real review settings, prioritizing biological plausibility and signal consistency over demographic optics.

Biomarkers of inflammation, metabolic control, gut barrier integrity, muscle function, and oxidative stress reflect conserved human biology. While baseline values may vary across populations due to lifestyle or environmental factors, the direction, magnitude, and interpretability of biological response remain consistent when trials are appropriately designed. This distinction is well understood by regulators and explains why such endpoints are routinely accepted across multinational development programs.

This approach is further reinforced by regulatory guidance on extrapolation, which recognizes that clinical data can be extended across populations when mechanistic consistency and biological plausibility are clearly established, even in the absence of locally conducted studies.

Quality, Not Distance, Determines Acceptance

In reality, regulatory skepticism is rarely about the population. When Indian clinical data fails to carry through a global filing, the fault almost always lies in the study itself due to endpoints that miss the mechanism, studies that are underpowered by design, variability that has not been accounted for, or because the trial loses alignment with its own hypothesis. Regulators recognise these weaknesses quickly, which is why post-hoc explanations no longer carry weight. What matters is whether quality has been built into the evidence from the outset, and whether the data can stand up as a coherent, biologically credible whole.

When these principles are met, Indian CROs and research sites are fully capable of delivering data packages that withstand global regulatory scrutiny, often with greater speed and cost efficiency.

Global Regulators Already Look Beyond Borders

Both the US FDA and EMA have long accepted foreign clinical data, provided it complies with Good Clinical Practice and can be scientifically validated in the context of the target population.

Regulators are not evaluating proximity. They are evaluating credibility.

Epigenetics, Lifestyle, and the Limits of Proximity

Growing recognition of epigenetics and lifestyle-driven gene expression further weakens proximity-based skepticism. Diet, physical activity, metabolic health, stress, and environmental exposure shape outcomes across all populations, often more dynamically than inherited genetic variation.

In nutrition, gut health, metabolic disease, and healthy aging, this means that well-characterized biological responses can be highly transferable when mechanisms are clear and endpoints are objective.

The global clinical ecosystem is quietly but decisively moving beyond borders and beyond bias. Regulators are no longer asking where evidence comes from; they are asking whether it can withstand scrutiny. Proximity does not rescue weak data, and distance does not diminish strong biology.

Indian clinical data continues to support global regulatory filings, not because expectations have been lowered, but because they have become precise. Modern regulatory science no longer separates East from West, or local from foreign. It applies a far stricter filter between evidence that is deliberately designed to endure scrutiny and evidence that is not. In today’s regulatory reality, geography explains nothing. Design explains everything.

Because good evidence doesn’t need a passport.

Reference

1. EMEA. ICH E5(R1): Ethnic factors in the acceptability of foreign clinical data. September 1998. Accessed April 23, 2026. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-5-r1-ethnic-factors-acceptability-foreign-clinical-data-step-5_en.pdf